Omnicell (OMCL) versus Its Peers Financial Contrast

Omnicell (NASDAQ:OMCL) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Omnicell to related businesses based on the strength of its institutional ownership, risk, earnings, analyst recommendations, valuation, profitability and dividends.

Volatility and Risk

Omnicell has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Omnicell’s rivals have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Omnicell and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0	1	7	1	3.00
Omnicell Competitors	4290	10574	18357	830	2.46

Omnicell presently has a consensus price target of $57.86, suggesting a potential upside of 60.24%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.80%. Given Omnicell’s stronger consensus rating and higher possible upside, research analysts clearly believe Omnicell is more favorable than its rivals.

Earnings & Valuation

This table compares Omnicell and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Omnicell	$1.18 billion	$2.05 million	37.61
Omnicell Competitors	$1.89 billion	$136.85 million	12.87

Omnicell’s rivals have higher revenue and earnings than Omnicell. Omnicell is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

97.7% of Omnicell shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Omnicell and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Omnicell	3.59%	5.69%	3.61%
Omnicell Competitors	-304.10%	-178.81%	-22.11%

Summary

Omnicell beats its rivals on 9 of the 13 factors compared.

About Omnicell

Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.